.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
McKinsey
Deloitte
Cipla
Novartis
McKesson
Merck
Baxter
Healthtrust
UBS

Generated: September 22, 2017

DrugPatentWatch Database Preview

Selegiline hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for selegiline hydrochloride and what is the scope of selegiline hydrochloride freedom to operate?

Selegiline hydrochloride
is the generic ingredient in three branded drugs marketed by Boscogen, Apotex, Somerset, G And W Labs Inc, Chartwell Molecules, Lannett Holdings Inc, Dava Pharms Inc, Mylan, Apotex Inc, Siegfried, and Valeant Pharm Intl, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for selegiline hydrochloride. Nine suppliers are listed for this compound.

Summary for Generic Name: selegiline hydrochloride

Tradenames:3
Patents:0
Applicants:11
NDAs:15
Drug Master File Entries: see list17
Suppliers / Packagers: see list9
Bulk Api Vendors: see list33
Clinical Trials: see list2,306
Patent Applications: see list745
Therapeutic Class:Antiparkinson Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:selegiline hydrochloride at DailyMed

Pharmacology for Ingredient: selegiline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
G And W Labs Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074744-001Jan 27, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 2006RXYesYes► Subscribe► Subscribe► Subscribe
Boscogen
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074912-001Apr 30, 1998ABRXNoNo► Subscribe► Subscribe► Subscribe
Siegfried
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074672-001Apr 1, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Lannett Holdings Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
CAPSULE;ORAL075145-001Sep 15, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Chartwell Molecules
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074565-001Aug 2, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
Somerset
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL019334-001Jun 5, 1989DISCNYesNo► Subscribe► Subscribe► Subscribe
Dava Pharms Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
CAPSULE;ORAL075352-001Nov 30, 1998ABRXNoNo► Subscribe► Subscribe► Subscribe
Somerset
ELDEPRYL
selegiline hydrochloride
CAPSULE;ORAL020647-001May 15, 1996ABRXYesYes► Subscribe► Subscribe► Subscribe
Apotex Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074871-001Jun 6, 1997ABRXNoYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: selegiline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 2006► Subscribe► Subscribe
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
Express Scripts
Boehringer Ingelheim
Argus Health
Baxter
Dow
US Department of Justice
Fuji
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot